Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2024 16:25 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
November 27, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics, Inc. Announces $8 Million Private Placement
November 25, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
November 12, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Open Letter to Shareholders

Open Letter to Shareholders
November 05, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
October 23, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
October 10, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
September 17, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 10, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
September 05, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate